No profile data available.
Avalo Therapeutics, Inc. (AVTX) is a healthcare company in the skin treatment pharmaceuticals industry, based in Wayne, United States, with about 33 full-time employees.
It reported revenue of $59,000 for fiscal year 2025, down 86.6% from fiscal year 2024, and net income of -$78.26 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $732.05 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc.
Avalo Therapeutics reported $59,000 in revenue for fiscal year 2025, down 86.6% from $441,000 in fiscal year 2024. In Q2 2026 revenue was $0.
$732.05 million as of October 9, 2026.
Listed companies of a similar size in the same industry (skin treatment pharmaceuticals) include Arcutis Biotherapeutics, Inc. (ARQT), Almirall, S.a. (ALMRY), Trevi Therapeutics, Inc. (TRVI), Aclaris Therapeutics, Inc. (ACRS).